CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Vaishali Pharma wins tenders for supply to Vanuatu & Samoa Islands
Apurva Joshi
/ Categories: Trending, Mindshare, DSIJ News

Vaishali Pharma wins tenders for supply to Vanuatu & Samoa Islands

Vaishali Pharma Limited has been awarded two tenders for the supply of surgical & pharma products to Vanuatu Islands and for the supply of surgical products to Samoa Islands. 

Vanuatu is a South Pacific Ocean nation made up of roughly 80 islands. The demand for healthcare products is increasing in Vanuatu Islands due to the increasing rates of non-communicable diseases (NCDs), death, and illness affecting the health of people. 

Samoa Islands is located in the Polynesian region of South Pacific Ocean, about halfway between Hawaii and New Zealand. The market of surgical products is increasing in Samoa Islands due to the increasing rates of premature mortality caused due to Alzheimer, blood pressure, and chronic heart diseases, etc. 

On the financial front, for the quarter ending December 2020, the company’s standalone revenue grew by 109 per cent to Rs 21.61 crore. Its EBITDA was up by 212 per cent and the EBITDA margin stood at 13.9 per cent. The net profit for the quarter increased 603 per cent to Rs 1.72 crore. 

Vaishali Pharma is amongst the leading players in the supply of pharma products-bulk drugs/APIs, formulations, surgical products, veterinary supplements, herbal & nutraceutical products, etc. It has over 150+ formulation brands marketed in multiple countries; of which, the dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 dossiers. 

In the early morning session on Monday, its stock was trading 2.9 per cent higher at Rs 38.70 from its previous close of Rs 37.60 on NSE. 

Previous Article Stocks that are likely to record significant movement on bourses today
Next Article Five stocks with selling interest
Print
665 Rate this article:
4.9
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR